Insider Transactions in Q3 2024 at Processa Pharmaceuticals, Inc. (PCSA)
Insider Transaction List (Q3 2024)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jul 10
2024
|
James H Stanker Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
282
-4.17%
|
$282
$1.71 P/Share
|
|
Jul 10
2024
|
James H Stanker Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
644
+8.69%
|
-
|
|
Jul 10
2024
|
Sian Bigora Chief Development Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
225
-1.02%
|
$225
$1.71 P/Share
|
|
Jul 10
2024
|
Sian Bigora Chief Development Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
644
+2.83%
|
-
|
|
Jul 10
2024
|
Patrick Lin Chief Business - Strategy Off |
SELL
Payment of exercise price or tax liability
|
Direct |
271
-0.92%
|
$271
$1.71 P/Share
|
|
Jul 10
2024
|
Patrick Lin Chief Business - Strategy Off |
BUY
Exercise of conversion of derivative security
|
Direct |
644
+2.15%
|
-
|
|
Jul 10
2024
|
David Young Pres. Research & Development |
SELL
Payment of exercise price or tax liability
|
Direct |
282
-0.35%
|
$282
$1.71 P/Share
|
|
Jul 10
2024
|
David Young Pres. Research & Development |
BUY
Exercise of conversion of derivative security
|
Direct |
644
+0.79%
|
-
|
|
Jul 10
2024
|
Wendy Guy Chief Administrative Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
220
-1.82%
|
$220
$1.71 P/Share
|
|
Jul 10
2024
|
Wendy Guy Chief Administrative Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
644
+5.06%
|
-
|